Experimental <it>in vivo</it> and <it>in vitro</it> treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to examine the efficacy of <i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2407/12/226 |